Pharmacogenomics (PGx) enables personalized treatment for the prediction of drug
response and to avoid adverse drug reactions. Currently, PGx mainly relies on the genetic …

Increased life expectancy, attributed to improved access to healthcare and drug
development, has led to an increase in multimorbidity, a key contributor to polypharmacy …

A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney
disease (CKD) compared with healthy volunteers (HVs), depending on the interplay …

The older population consisting of persons aged 65 years or older is the fastest-growing
population group and also the major consumer of pharmaceutical products. Due to the …

Background and Objectives P-glycoprotein (P-gp) is one of the most intensely studied
transporters owing to its broad tissue distribution and substrate specificity. Existing research …

Infections are important factors contributing to the morbidity and mortality among elderly
patients. High rates of consumption of antimicrobial agents by the elderly may result in …

Background and aims Around 850 million people worldwide are affected by chronic kidney
disease (CKD). Patients with CKD often develop malnutrition and sarcopenia and changes …

The role of transporters in drug clearance is widely acknowledged, directly and indirectly by
facilitating tissue/enzyme exposure. Through the latter, transporters also affect volume of …

Dabigatran etexilate (DABE) is a clinical probe substrate for studying drug-drug interaction
(DDI) through an intestinal P-glycoprotein (P-gp). A recent in vitro study, however, has …